TLX is valued at $2B for several reasons, but primarily due to advanced development stage of is product candidates. One of these, Illuccix, is now a commercial product generating revenue given recent approval by the TGA in Australia. This suggests FDA is more likely to also approve Illuccix in late December. If this occurs they can aim for $30M revenue in US p.a. Then they have a second product coming, as well as some high value cancer therapy products. CU6 and RAD are good but very early stage. Plus TLX management is exceptional. As always PDYOR.
- Forums
- ASX - By Stock
- RAD
- IPO - Radiopharm Theranostics Limited - 25 November 2021 11:00 AM AEDT ##
IPO - Radiopharm Theranostics Limited - 25 November 2021 11:00 AM AEDT ##, page-79
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAD (ASX) to my watchlist
|
|||||
Last
3.3¢ |
Change
-0.001(2.94%) |
Mkt cap ! $68.61M |
Open | High | Low | Value | Volume |
3.6¢ | 3.6¢ | 3.3¢ | $27.60K | 803.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 1096772 | 3.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.6¢ | 119999 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 1096772 | 0.033 |
6 | 257119 | 0.032 |
5 | 222255 | 0.031 |
4 | 264200 | 0.030 |
2 | 175749 | 0.028 |
Price($) | Vol. | No. |
---|---|---|
0.036 | 119999 | 1 |
0.037 | 375000 | 4 |
0.038 | 345162 | 5 |
0.039 | 652860 | 3 |
0.040 | 730704 | 5 |
Last trade - 15.02pm 04/09/2024 (20 minute delay) ? |
Featured News
RAD (ASX) Chart |